Allergan reports mixed data for acute migraine candidate in second Phase III

Allergan plc (NYSE:AGN) said the 50 mg dose of ubrogepant (MK-1602) met the co-primary endpoints in the double-blind, U.S. Phase III ACHIEVE II trial for the acute treatment of migraine. However, the 25 mg dose of the candidate only met one

Read the full 415 word article

User Sign In